Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

Laura Walsh, Venkata Preetam Sandeep Kaduluri, Amy DeZern, Gabrielle Prince, Jonathan Webster, Tania Jain, Theodoros Karantanos, William Dalton, Ivana Gojo, Alex Ambinder, B. Douglas Smith, Lukasz Gondek, Mark Levis, Gabriel Ghiaur

Blood (2025) 146 (Supplement 1): 5227.

https://doi.org/10.1182/blood-2025-5227

Published: 2025

Journal Articles

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study

Christina Sotiropoulou, Christos Kontos, Anthi Bouchla, Theodora Chatziligeroudi, Sotiris Papageorgiou, Agni Vitsioti, Christina Apostolopoulou, Ioulia Markaki, Georgia Karamanou, Theodoros Karantanos, Vassiliki Pappa

Blood (2025) 146 (Supplement 1): 6799.

https://doi.org/10.1182/blood-2025-6799

Published: 2025

Journal Articles

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Shirley Mo, Alex Ambinder, Amy DeZern, B. Douglas Smith, Ephraim Fuchs, Gabriel Ghiaur, Gabrielle Prince, Ivana Gojo, Javier Bolanos-Meade, Jonathan Webster, Lukasz Gondek, Richard Jones, Tania Jain, Theodoros Karantanos, William Dalton, Mark Levis

Blood (2025) 146 (Supplement 1): 1710.

https://doi.org/10.1182/blood-2025-1710

Published: 2025

Journal Articles

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

John Claiborne, Venkata Preetam Sandeep Kaduluri, Hua-Ling Tsai, Ivana Gojo, Amy DeZern, B. Douglas Smith, Tania Jain, Gabrielle Prince, Javier Bolanos-Meade, Ephraim Fuchs, Gabriel Ghiaur, Lukasz Gondek, William Dalton, Theodoros Karantanos, Ravi Varadhan, Mark Levis, Richard Jones, Jonathan Webster, Alex Ambinder

Blood (2025) 146 (Supplement 1): 44.

https://doi.org/10.1182/blood-2025-44

Published: 2025

Journal Articles

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

John Preston Claiborne, Daniel Li, B. Douglas Smith, Mark J. Levis, Ivana Gojo, Amy E. DeZern, Alexander J. Ambinder, Tania Jain, Gabrielle T. Prince, Lukasz P. Gondek, Theodoros Karantanos, Gabriel Ghiaur, William Brian Dalton, Jonathan Allen Webster

Blood (2024) 144 (Supplement 1): 5904.

https://doi.org/10.1182/blood-2024-207608

Published: 2024

Journal Articles

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

Blood (2024) 144 (Supplement 1): 3551.

https://doi.org/10.1182/blood-2024-212141

Published: 2024

Journal Articles

CCRL2 As a Novel Target in Acute Erythroid Leukemia

Nour Naji, Taha Ahmedna, Theodora Chatzilygeroudi, Tushar Nichakawade, Sean Lee, Brandy Perkins, Chen Lossos, Bogdan Paun, Evangeline Watson, Rena R. Xian, Styliani Karanika, Rick Jones, Suman Paul, Theodoros Karantanos

Blood (2024) 144 (Supplement 1): 828.

https://doi.org/10.1182/blood-2024-205991

Published: 2024

Journal Articles

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Tessa Seale, Brandy Perkins, Theodora Chatzilygeroudi, Soren Cole, Kareem Battah, Maximilian Stahl, Mark J. Levis, Alexander J. Ambinder, Sandra Misale, Theodoros Karantanos

Blood (2024) 144 (Supplement 1): 5784.

https://doi.org/10.1182/blood-2024-211218

Published: 2024

Journal Articles

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Ilias Sinanidis, Michael Jamie Hochman, Hua-Ling Tsai, Michael P Randall, Brandon Bonilla, Ravi Varadhan, Alexander Joseph Ambinder, Amy E. DeZern, Theodoros Karantanos

Blood (2023) 142 (Supplement 1): 3229.

https://doi.org/10.1182/blood-2023-187247

Published: 2023

Journal Articles

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Blood (2022) 140 (Supplement 1): 7731–7733.

https://doi.org/10.1182/blood-2022-157985

Published: 2022

Journal Articles

CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells

Theodoros Karantanos, Christopher Esteb, Patric Teodorescu, Brandy Perkins, Ilias Christodoulou, Stamatia Vorri, Trivikram Rajkhowa, William Brian Dalton, Gabriel Ghiaur, Richard J. Jones

Blood (2022) 140 (Supplement 1): 5866–5867.

https://doi.org/10.1182/blood-2022-159538

Published: 2022

Journal Articles

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Theodoros Karantanos, Hua-Ling Tsai, Mark Levis, Ravi Varadhan, Richard J. Jones, Tania Jain

Blood (2021) 138 (Supplement 1): 1520.

https://doi.org/10.1182/blood-2021-151624

Published: 2021

Journal Articles

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

Theodoros Karantanos, MDPhD, Hua-Ling Tsai, ScM, Lukasz P. Gondek, MDPhD, Mark Levis, MD PhD, Margaret M. Showel, MD, Amy E. DeZern, MD, Ivana Gojo, MD, Ravi Varadhan, PhD, Richard J. Jones, MD, Tania Jain, MD

Blood (2020) 136 (Supplement 1): 40.

https://doi.org/10.1182/blood-2020-138671

Published: 2020

Journal Articles

ATM Germline Variant Increases the Risk of MPN Progression

Theodoros Karantanos, MD PhD, Shruti Chaturvedi, MBBS, MS, Christopher D Gocke, MD, Donna Marie Williams, PhD, Alison R. Moliterno, MD, Evan M Braunstein, MD PhD

Blood (2019) 134 (Supplement_1): 835.

https://doi.org/10.1182/blood-2019-125362

Published: 2019

Journal Articles

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Theodoros Karantanos, MD PhD, Evan M Braunstein, MD PhD, Shruti Chaturvedi, MBBS, MS, Jerry L. Spivak, MD, Linda Resar, MD, Styliani Karanika, MD, Donna Marie Williams, PhD, Christopher D Gocke, MD, Alison R. Moliterno, MD

Blood (2019) 134 (Supplement_1): 837.

https://doi.org/10.1182/blood-2019-125393

Published: 2019

Journal Articles

Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms

Theodoros Karantanos, MDPhD, Shruti Chaturvedi, MBBS,MS, Jerry L. Spivak, MD, Linda Resar, MD, Evan M Braunstein, MDPhD, Styliani Karanika, MD, Donna Marie Williams, PhD, Ophelia Rogers, Alison R. Moliterno, MD

Blood (2018) 132 (Supplement 1): 1768.

https://doi.org/10.1182/blood-2018-99-112683

Published: 2018

Journal Articles

Assessment of a Multi-Cytokine Profile By a Novel Biochip-Based Assay Reveals Unique Correlation Patterns with Immune Reconstitution after Cord Blood Transplantation in Adults

Theodoros Karantanos, MD, Haesook T Kim, PhD, Lequn Li, MD PhD, Corey Cutler, MD MPH, FRCPC, Joseph H. Antin, MD, Karen Ballen, MD, Jerome Ritz, MD, Ioannis Politikos, MD, Vassiliki A Boussiotis, MD PhD

Blood (2017) 130 (Supplement 1): 1980.

https://doi.org/10.1182/blood.V130.Suppl_1.1980.1980

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms

PPP1R15A as a therapeutic target to overcome chemoresistance in AML: An in vitro study

DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors

Post-allogeneic hematopoietic cell transplantation outcomes are similar after hypomethylating agent/venetoclax and intensive, cytarabine-based remission induction for Acute Myeloid Leukemia when using standardized, contemporary transplant techniques

Efficacy and Tolerability of Blinatumomab in Clinical Trial Ineligible Patients with CD19+ Leukemias

Acute Lymphoblastic Leukemia (ALL) Outcomes after Allogeneic Blood or Marrow Transplantation (alloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) in the Era of More Effective Pre-Transplant Therapy

CCRL2 As a Novel Target in Acute Erythroid Leukemia

Pan-RAS Inhibitor RMC-7977 Overcomes Oncogenic RAS Signaling and Exerts Antileukemic Effects in CMML/AML Cells

Favorable Outcomes for High-Risk MDS and Oligoblastic AML with MDS-Related Changes with Reduced Intensity Allogeneic Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide

Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

CCRL2 Promotes Cytokine-Regulated Growth of Erythroleukemia Cells

The Presence of SETBP1 , RUNX1 or EZH2 Mutation in MDS/MPN Is Associated with Absence of Response to Hypo-Methylating Agents

Allogeneic Blood or Marrow Transplantation (BMT) with Post-Transplantation Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis for Myelodysplastic Syndrome/ Myeloproliferative Neoplasm-Overlap Syndromes (MDS/MPN)

ATM Germline Variant Increases the Risk of MPN Progression

Worse Outcomes in Males with MPN Are Associated with Qualitative and Quantitative Differences in Non-Driver Mutational Burden

Independent Association of Male Sex with Presentation and Clinical Outcomes in Myeloproliferative Neoplasms

Assessment of a Multi-Cytokine Profile By a Novel Biochip-Based Assay Reveals Unique Correlation Patterns with Immune Reconstitution after Cord Blood Transplantation in Adults

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only